- In April 2023, Boehringer Ingelheim International GmbH announced positive Phase II clinical trial results for its novel selective Cyclooxygenase 1 Inhibitor targeting inflammatory bowel disease (IBD). The drug demonstrated a 39% improvement in symptom control over placebo and has advanced to Phase III trials. This reinforces the company's commitment to targeted anti-inflammatory therapies and supports its growing portfolio in gastrointestinal health
- In March 2023, Pfizer Inc. launched a strategic expansion of its COX-1 inhibitor production capacity in North America, responding to a 21% year-over-year increase in demand for its NSAID-based pain management therapies. This expansion highlights Pfizer’s strategy to maintain its leadership in the non-opioid analgesic market while addressing rising demand for safer anti-inflammatory alternatives
- In March 2023, Cipla Ltd. partnered with Zydus Group (India) to co-develop and commercialize a new class of non-selective Cyclooxygenase inhibitors for chronic osteoarthritis management. The collaboration aims to capitalize on India’s growing pharmaceutical market, which accounts for 8.4% CAGR growth in the COX-1 segment between 2025 and 2032, and enhance global supply chain resilience
- In February 2023, Teva Pharmaceutical Industries Ltd. introduced an improved formulation of its over-the-counter COX-1 inhibitor brand, offering 15% better gastrointestinal tolerability based on clinical feedback. The update is part of the company’s initiative to enhance patient compliance and safety profiles amid rising regulatory scrutiny in Europe and North America
- In January 2023, Novartis AG began post-marketing surveillance of its selective COX-1 inhibitor across six European countries, aiming to evaluate long-term cardiovascular safety. The move follows growing regulatory emphasis on adverse event monitoring and contributes to Novartis’ global safety leadership across the NSAID and pain relief categories
- In January 2023, Alembic Pharmaceuticals Ltd. reported a 12% revenue increase in its pain management segment, largely driven by its COX-1 inhibitor sales in Asia-Pacific markets. This marks Alembic’s continued penetration into emerging markets and reinforces its focus on affordable and accessible anti-inflammatory drug manufacturing
